Potential contribution of PrEP uptake by adolescents 15-17 years old to achieving the "Ending the HIV Epidemic" incidence reduction goals in the US South.

Deven T Hamilton, Li Yan Wang, Karen W Hoover, Dawn K Smith, Kevin P Delaney, Jingjing Li, Tamika Hoyte, Samuel M Jenness, Steven M Goodreau
Author Information
  1. Deven T Hamilton: Center for Studies in Demography and Ecology, University of Washington, Seattle, WA, United States of America. ORCID
  2. Li Yan Wang: Division of Adolescent and School Health, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
  3. Karen W Hoover: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  4. Dawn K Smith: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  5. Kevin P Delaney: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  6. Jingjing Li: Division of Adolescent and School Health, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
  7. Tamika Hoyte: National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  8. Samuel M Jenness: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
  9. Steven M Goodreau: Departments of Anthropology and Epidemiology, University of Washington, Seattle, Washington, United States of America. ORCID

Abstract

BACKGROUND: The "Ending the HIV Epidemic" (EHE) initiative seeks to reduce new HIV infections in the U.S. by prioritizing federal resources towards highly impacted populations. Antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are essential for reaching EHE goals. Adolescents are often at increased risk for HIV because they may lack agency in negotiating their sexual partnerships and may not have the same access to treatment and prevention as adults. This study estimates the potential contribution of expanded PrEP coverage among adolescents ages 15-17 to achieving the EHE goals in the South.
METHODS: An HIV-transmission model was built to simulate the HIV epidemic in the South. Increased ART and PrEP uptake were systematically varied with and without PrEP eligibility including individuals age<18.
RESULTS: Prioritizing PrEP for adolescents had a negligible impact on incidence. At 50% uptake among eligible adolescents and 90% ART coverage, including adolescents only improved the percentage of infections averted from 80.1% to 80.3%. In 10 of 15 scenarios explored, there was no reduction in new infections when PrEP eligibility was expanded to include adolescents age<18. At 95% ART coverage at the population-level incidence among adolescents declined by over 80%, but PrEP uptake among adolescents did not contribute to additional declines in incidence among adolescents.
CONCLUSIONS: Prioritizing PrEP for adolescents did not significantly contribute to reaching EHE incidence reductions goal. Focusing resources to specific adolescent populations at risk, such sexual minority males in high incidence settings, will remain an important public health goal outside the context of EHE.

References

  1. N Engl J Med. 2010 Dec 30;363(27):2587-99 [PMID: 21091279]
  2. J Adolesc Health. 2020 Jan;66(1):100-106 [PMID: 31757626]
  3. Am J Public Health. 2018 Nov;108(S4):S284-S291 [PMID: 30383415]
  4. J Acquir Immune Defic Syndr. 2020 Aug 15;84(5):443-452 [PMID: 32692102]
  5. J R Stat Soc Series B Stat Methodol. 2014 Jan 1;76(1):29-46 [PMID: 24443639]
  6. J Adolesc Health. 2021 Mar;68(3):488-496 [PMID: 32798099]
  7. AIDS. 2020 Nov 15;34(14):2103-2113 [PMID: 32910062]
  8. Arch Sex Behav. 2020 Jan;49(1):211-216 [PMID: 31667642]
  9. J Gen Intern Med. 2017 Feb;32(2):192-198 [PMID: 27761767]
  10. J Adolesc Health. 2015 Oct;57(4):407-12 [PMID: 26318671]
  11. JAMA Pediatr. 2017 Nov 1;171(11):1063-1071 [PMID: 28873128]
  12. J Infect Dis. 2021 Jan 4;223(1):72-82 [PMID: 32882043]
  13. JMIR Public Health Surveill. 2016 Apr 21;2(1):e14 [PMID: 27227149]
  14. MMWR Recomm Rep. 2020 Apr 24;69(3):1-12 [PMID: 32324724]
  15. Curr HIV/AIDS Rep. 2019 Feb;16(1):120-128 [PMID: 30707399]
  16. J Adolesc Health. 2018 Mar;62(3):311-319 [PMID: 29248392]
  17. JAMA. 2019 Mar 5;321(9):844-845 [PMID: 30730529]
  18. J Assoc Nurses AIDS Care. 2007 Mar-Apr;18(2):78-82 [PMID: 17403499]
  19. J Stat Softw. 2008;24(1):1548-7660 [PMID: 18618019]
  20. Ann Epidemiol. 2018 Dec;28(12):841-849 [PMID: 29983236]
  21. J Stat Softw. 2008 May 1;24(3):nihpa54860 [PMID: 19756229]
  22. Ann Intern Med. 2021 Nov;174(11):1542-1553 [PMID: 34543589]
  23. Lancet. 2021 Mar 20;397(10279):1095-1106 [PMID: 33617774]
  24. J Acquir Immune Defic Syndr. 2016 May 1;72(1):79-86 [PMID: 26745827]
  25. Pediatrics. 2020 Jan;145(1): [PMID: 31857381]
  26. AIDS. 2019 Mar 15;33(4):701-708 [PMID: 30585840]
  27. J Stat Softw. 2018 Apr;84: [PMID: 29731699]
  28. JAMA. 2019 Jun 11;321(22):2203-2213 [PMID: 31184747]
  29. J Infect Dis. 2016 Mar 1;213(5):776-83 [PMID: 26486637]
  30. J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S18-24 [PMID: 20571419]
  31. Clin Infect Dis. 2013 Apr;56(8):1149-55 [PMID: 23223604]
  32. N Engl J Med. 2012 Aug 2;367(5):399-410 [PMID: 22784037]
  33. BMC Public Health. 2023 Apr 20;23(1):716 [PMID: 37081482]
  34. Clin Infect Dis. 2018 Mar 5;66(6):936-944 [PMID: 29069298]
  35. JAMA Intern Med. 2016 Jan;176(1):75-84 [PMID: 26571482]
  36. Epidemics. 2020 Jan 24;30:100386 [PMID: 32004795]
  37. Sex Transm Dis. 2019 Jun;46(6):357-363 [PMID: 31095100]
  38. J Med Internet Res. 2020 Oct 23;22(10):e23173 [PMID: 33095177]

Grants

  1. P2C HD042828/NICHD NIH HHS
  2. R21 MH112449/NIMH NIH HHS

MeSH Term

Adult
Male
Humans
Adolescent
HIV Infections
Goals
Incidence
Anti-HIV Agents
Sexual and Gender Minorities
Pre-Exposure Prophylaxis

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0adolescentsPrEPincidenceHIVEHEamongARTuptakeinfectionsgoalscoverageSouth"EndingEpidemic"newresourcespopulationsreachingriskmaysexualcontributionexpanded15-17achievingeligibilityincludingage<18Prioritizing80reductioncontributegoalBACKGROUND:initiativeseeksreduceUSprioritizingfederaltowardshighlyimpactedAntiretroviraltherapypre-exposureprophylaxisessentialAdolescentsoftenincreasedlackagencynegotiatingpartnershipsaccesstreatmentpreventionadultsstudyestimatespotentialagesMETHODS:HIV-transmissionmodelbuiltsimulateepidemicIncreasedsystematicallyvariedwithoutindividualsRESULTS:negligibleimpact50%eligible90%improvedpercentageaverted1%3%1015scenariosexploredinclude95%population-leveldeclined80%additionaldeclinesCONCLUSIONS:significantlyreductionsFocusingspecificadolescentminoritymaleshighsettingswillremainimportantpublichealthoutsidecontextPotentialyearsoldUS

Similar Articles

Cited By